Artiva Biotherapeutics, Inc. Payments of Stock Issuance Costs
Artiva Biotherapeutics, Inc. (ARTV) reported Payments of Stock Issuance Costs of $17.30 million for the 1-month period ending 2026-05-31, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. payments of stock issuance costs for the quarter ending 2024-12-31 was $20.00K.
- Artiva Biotherapeutics, Inc. payments of stock issuance costs for the quarter ending 2024-09-30 was $2.60M.
- Artiva Biotherapeutics, Inc. payments of stock issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. payments of stock issuance costs for fiscal 2024 was $4.18M.
| Period end | Payments of Stock Issuance Costs 1 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2026-05-31 | $17.30M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 | ||||
| 2024-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.62M derived: sum of 2 quarters · filed 2026-03-10 | $4.18M 10-K · filed 2026-03-10 | ||
| 2024-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.16M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $1.56M 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |